Behavioral Neurobiology of Psychedelic Drugs

1. Front Matter

   Pages i-x

   PDF

2. Chemistry and Structure–Activity Relationships of Psychedelics

   • David E. Nichols

   Pages 1-43

3. Hallucinogens and Serotonin 5-HT2A Receptor-Mediated Signaling Pathways

   • Juan F. López-Giménez, Javier González-Maeso

   Pages 45-73

4. Effects of Hallucinogens on Neuronal Activity

   • L. Lladó-Pelfort, P. Celada, M. S. Riga, E. Troyano-Rodríguez, N. Santana, F. Artigas

   Pages 75-105

5. Interactions of Hallucinogens with the Glutamatergic System: Permissive Network Effects Mediated Through Cortical Layer V Pyramidal Neurons

   • Gerard J. Marek

   Pages 107-135

6. The Effects of Hallucinogens on Gene Expression

   • David A. Martin, Charles D. Nichols

   Pages 137-158

7. Effect of Hallucinogens on Unconditioned Behavior

   • Adam L. Halberstadt, Mark A. Geyer

   Pages 159-199

8. Hallucinogens in Drug Discrimination

   • Lisa E. Baker

   Pages 201-219

9. Phenomenology, Structure, and Dynamic of Psychedelic States

   • Katrin H. Preller, Franz X. Vollenweider

   Pages 221-256

10. Serotonergic Hallucinogen-Induced Visual Perceptual Alterations

    • Michael Kometer, Franz X. Vollenweider

    Pages 257-282

11. New World Tryptamine Hallucinogens and the Neuroscience of Ayahuasca

    • Dennis McKenna, Jordi Riba

    Pages 283-311

12. Experimental Psychosis Research and Schizophrenia—Similarities and Dissimilarities in Psychopathology

    • Leo Hermle, Rainer Kraehenmann

    Pages 313-332

13. A Review of Hallucinogen Persisting Perception Disorder (HPPD) and an Exploratory Study of Subjects Claiming Symptoms of HPPD

    • John H. Halpern, Arturo G. Lerner, Torsten Passie

    Pages 333-360

14. Therapeutic Applications of Classic Hallucinogens

    • Michael P. Bogenschutz, Stephen Ross

    Pages 361-391

15. Classic Hallucinogens and Mystical Experiences: Phenomenology and Neural Correlates

    • Frederick S. Barrett, Roland R. Griffiths

    Pages 393-430

16. Erratum to: Phenomenology, Structure, and Dynamic of Psychedelic States

    • Katrin H. Preller, Franz X. Vollenweider

    Pages 1-1

This volume brings together the latest basic and clinical research examining the effects and underlying mechanisms of psychedelic drugs. Examples of drugs within this group include LSD, psilocybin, and mescaline. Despite their structural differences, these compounds produce remarkably similar experiences in humans and share a common mechanism of action.  Commonalities among the substances in this family are addressed both at the clinical and phenomenological level and at the basic neurobiological mechanism level. To the extent possible, contributions relate the clinical and preclinical findings to one another across species. The volume addresses both the risks associated with the use of these drugs and the potential medical benefits that might be associated with these and related compounds.

• MDMA
• entactogens
• hallucinogens
• psychedelics
• psychotomimetics
• psychopharmacology

“This book brings together the latest basic and clinical research into the underlying mechanism of action, effects, and possible clinical uses of psychedelic drugs. … It brings together current knowledge regarding this class of drugs pharmacology, neurobiological effects, subjective experience, and therapeutic effects. … It brings together preclinical and clinical data, which will be of interest to anyone involved with or curious about this category of drugs.” (Michael Easton, Doody's Book Reviews, September, 2018)

• Department of Psychiatry, University of California San Diego, La Jolla, USA

  Adam L. Halberstadt

• Psychiatric University Hospital, Heffter Research Center Zurich, University of Zurich, Zurich, Switzerland

  Franz X. Vollenweider

• Division of Chemical Biology and Medicinal Chemistry, University of North Carolina, Chapel Hill, USA

  David E. Nichols

Policies and ethics